AMLchemy at ASH: Brewing Success with Menin Magic, MRD Mysteries, and Aza/Ven Alchemy

https://is1-ssl.mzstatic.com/image/thumb/Podcasts116/v4/44/1e/84/441e8404-cfcd-d5ea-5cd7-20bcae5f4165/mza_9369316362601325051.jpg/600x600bb.jpg

WolverHeme Happy Hour

Bernard Marini, Anthony Perissinotti, et al.

41 episodes

3 days ago

Welcome to WolverHeme Happy Hour! This is a podcast dedicated to all things hematology! We discuss new data, debate controversial therapies, and talk about new and exciting research. While we nerd out about data, we'll have a few drinks! Disclaimer: The views and opinions expressed on this podcast are solely those of the podcasters and guests and do not reflect the views or opinions of our employers or other affiliations.

Medicine

Health & Fitness

RSS

All content for WolverHeme Happy Hour is the property of Bernard Marini, Anthony Perissinotti, et al. and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/22883740/22883740-1646962011003-b3603219ae0ba.jpg

AMLchemy at ASH: Brewing Success with Menin Magic, MRD Mysteries, and Aza/Ven Alchemy

WolverHeme Happy Hour

41 minutes 13 seconds

1 year ago

AMLchemy at ASH: Brewing Success with Menin Magic, MRD Mysteries, and Aza/Ven Alchemy

In this episode, Anthony and Bernie discuss the AML abstracts at ASH that we found most intriguing and controversial!

Abstracts:

FILO - Stopping Aza/Ven: https://ash.confex.com/ash/2023/webprogram/Paper185437.html
Revumenib Late Breaking Abstract: https://ash.confex.com/ash/2023/webprogram/Paper192042.html
JNJ617 Menin Inhibitor Data: https://ash.confex.com/ash/2023/webprogram/Paper172422.html
SAVE Trial (Revumenib + PO Dec/ven): https://ash.confex.com/ash/2023/webprogram/Paper182337.html
Dec/Ven vs. 3+7 Randomized Phase II: https://ash.confex.com/ash/2023/webprogram/Paper181347.html
NCRI AML18 RCT: https://ash.confex.com/ash/2023/webprogram/Paper185956.html
Impact of NPM1+/FLT3+/MRD in AML17 and AML19: https://ash.confex.com/ash/2023/webprogram/Paper179033.html
CBF and NPM1 MRD: https://ash.confex.com/ash/2023/webprogram/Paper184848.html
Persistent MRD by PCR but Flow Negativity in CBF AML (Mast Cell Madness): https://ash.confex.com/ash/2023/webprogram/Paper180275.html
MORPHO More MRD Analysis: https://ash.confex.com/ash/2023/webprogram/Paper177929.html